Niakan E, Bertorini T E, Acchiardo S R, Werner M F
Arch Neurol. 1981 Jun;38(6):378-9. doi: 10.1001/archneur.1981.00510060080016.
Because procainamide hydrochloride (Pronestyl) may block neuromuscular transmission (NMT), this drug is contraindicated in cases of myasthenia gravis. Reduction of the safety factor of NMT is also seen in other conditions, including peripheral neuropathies. A patient with uremic peripheral neuropathy in whom myasthenia-like weakness developed during procainamide therapy is described. Procainamide should be given with caution in cases of peripheral neuropathies in which there may be a reduction of the safety factor of NMT.
由于盐酸普鲁卡因胺（普罗帕酮）可能会阻断神经肌肉传导（NMT），因此重症肌无力患者禁用此药。在其他病症中，包括周围神经病变，也可见NMT安全系数降低的情况。本文描述了一名患有尿毒症性周围神经病变的患者，其在接受普鲁卡因胺治疗期间出现了类似重症肌无力的肌无力症状。对于可能存在NMT安全系数降低的周围神经病变患者，应谨慎使用普鲁卡因胺。
